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Abstract
Despite the success of immunotherapy in several haematological neoplasms, the ef-
fectiveness in acute myeloid leukaemia (AML) is still controversial, partially due to 
the lack of knowledge regarding immune-related processes in this disease and similar 
neoplasias. In this study, we analysed the role and expression of histamine receptor 
1 (HRH1) in haematological malignancies. Although the histamine receptor type 1 
was widely expressed in healthy and malignant haematopoiesis, especially along the 
myeloid lineage, HRH1 lacked a relevant role in survival/proliferation and chemore-
sistance of AML cells, as analysed by HRH1 knockdown (KD) and pharmacological 
modulation. However, HRH1-mediated signalling was critical for the activation of 
the differentiation process induced by several agents including all-trans retinoic acid, 
establishing a role for HRH1 in myeloid differentiation. Pharmacological activation 
of Erk was able to partially restore differentiation capacity in HRH1 KD AML cells, 
suggesting that HRH1 signalling acts upstream MAPK-Erk pathway. As an indirect 
consequence of our results, treatment-related histamine release is not expected to 
confer a proliferative advantage in leukaemic cells.
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Acute myeloid leukaemia (AML) is a haematological neoplasia char-
acterized by the accumulation in bone marrow of transformed 
myeloid progenitors with enhanced proliferation and a block in dif-
ferentiation. Indeed, AML cells are arrested at different stages of 
myeloid maturation.1 Among the plethora of known role-players in 
myeloid differentiation, the histaminergic system has been recently 
described as a regulator of healthy and malignant haematopoiesis, 
mainly through the modulation by histamine of myeloid-biased hae-
matopoietic stem cell quiescence2 and the production of ROS in im-
mature blasts.3,4
Histamine is a pleiotropic biogenic amine acting through four 
different histamine receptors (HRH1 to HRH4) belonging to the G 
protein-coupled receptor superfamily. Although most of the pro-
posed effects of histamine on myeloid differentiation are mediated 
by HRH2,2,3 the expression of HRH1 in AML cell lines has recently 
been reported.5 Nevertheless, no role for HRH1 in leukaemia has 
been identified.
To inquire on that open question, we first examined HRH1 ex-
pression in blood cell subsets from healthy donors, as well as in 
samples from patients with AML (Table S1) and the related myeloid 
malignancies chronic myelomonocytic leukaemia (CMML) (Table S2) 
and myelodysplastic syndromes (MDS) (Table S3). Regarding healthy 
cells, the expression differed greatly across subtypes; no expression 
was detected in primitive cord blood cells (CD45+ CD34+), T cells 
(CD45+ CD3+) and platelets (CD45− CD41a+), while intermediate ex-
pression was observed for B cells (CD45+ CD19+) and granulocytes 
(CD45+ CD15+) (Figure 1A). Monocyte-macrophage cells (CD45+ 
CD14+) showed a generalized HRH1 expression. Consistent with 
their molecular heterogeneity, HRH1 expression showed a wide 
distribution pattern in MDS and AML, ranging from 0% to 100%. 
Conversely, in CMML HRH1 expression was prevalent, reaching 
more than 50% in all 17 analysed samples (Figure 1A). These results, 
similar to healthy monocytes, are in agreement with the rather ho-
mogeneous nature of CMML cells, whose phenotype resembles dif-
ferentiated monocytes.6 Similarly, in CMML, classical (CD14+ CD16−) 
and intermediate (CD14+ CD16+) monocytes are predominant,6 and 
they both consistently express HRH1, in contrast to non-classical 
CD14dimCD16+ monocytes (Figure 1A). Given this HRH1 expression 
pattern in AML, we next interrogated the role of HRH1 signalling 
on cellular viability and clonogenic capacity both in primary AML 
samples and healthy donor cells. As we have previously described 
cytotoxic effects of several antihistamines based on their physico-
chemical properties and independently of HRH1,5 we selected fex-
ofenadine and cetirizine, potent HRH1 antagonists devoid of these 
properties. In all healthy samples, agonism or antagonism of HRH1 
produced no significant effects on the clonogenicity, while on neo-
plasic ones only histamine caused a slight reduction (Figure 1B,C). 
The exception was a slight bias towards granulocytic differentiation 
of umbilical cord blood (UCB)-derived haematopoietic progenitor/
stem cells (HPSCs) upon treatment with histamine (Figure 1D).
To further study the role of HRH1 expression by AML, we gen-
erated an HL60-derived cell line stably expressing a CRISPR/Cas9-
mediated HRH1 down-regulation system. The knockdown (KD) of 
HRH1 was assessed at a protein level both by flow cytometry and 
Western blot and was highly efficient (Figure 2A). KD of HRH1 re-
sulted in a moderate increase in colony-forming capacity (Figure 2B) 
and no significant changes in sensitivity to the commonly used che-
motherapeutic cytarabine (Figure 2C) or histamine (Figure S1). Thus, 
HRH1 is probably not crucially involved in proliferation and chemo-
sensitivity in HL-60, although it may play a residual role in attenuat-
ing self-renewal.
As one of the main features of AML is the maturation blockade 
and some effects of histamine have been observed on myeloid dif-
ferentiation,7 we next interrogated the effects of HRH1 signalling 
on sensitivity to differentiation-inducing agents. We treated control 
and HRH1-KD AML cells with three different differentiation-induc-
ing agents modulating diverse pathways; the all-trans retinoic acid 
(ATRA), vitamin D3 and the phorbol ester mezerein. Contrary to 
cytarabine sensitivity, HRH1 KD resulted in a drastic decrease in 
ATRA- and vitamin D3-induced differentiation and a milder effect 
on response to mezerein, as assessed by surface expression levels 
of the CD11b (Figure 2D) and CD14 (Figure S2) myeloid-associated 
differentiation markers. This was also observed for viability and clo-
nogenicity (Figures S2). At a morphological level, HRH1 KD did not 
elicit in any major alteration in the basal state, while the decrease 
in ATRA response could also be confirmed (Figure 2E). As HRH1 
surface level recapitulated the maturation status of blood cells 
(Figure 1A) and its signalling modulated the response to differenti-
ation stimuli (Figure 2D), we further investigated the receptor traf-
ficking during the differentiation process. ATRA exposure resulted in 
a more than 2-fold increase in HRH1 expression, while no significant 
effects in vitamin D3- and mezerein-treated cells could be observed 
(Figure 2F). HRH2 was slightly up-regulated in the presence of ATRA 
in HRH1-KD cells (Figure S3A), whereas HRH3 and HRH4 are not 
expressed on these cells (Figure S3B). These observations strength-
ened the relationship between HRH1 signalling and myeloid differ-
entiation and suggested that it may rely on specific pathways, given 
the fact that only ATRA exposure could elicit an increase in HRH1.
To seek for mechanistic explanations for the role of HRH1 in 
AML differentiation, we probed publicly available AML expression 
data in the R2 Genomics (https://hgser ver1.amc.nl), performing a 
GSEA analysis on the top genes correlated with HRH1 in 4 different 
AML datasets. The KEGG retinol metabolism gene set recurrently 
appeared on top of the analyses (Figure S4). Given our previous re-
sults regarding ATRA response and previous studies highlighting the 
pro-differentiation effects on AML of inhibiting CYP26, a key player 
in retinol metabolism,8 we next combined ATRA and the CYP26 in-
hibitor talarozole in control and HRH1-KD HL60 cells. By inhibiting 
CYP26, we prevent the metabolization of ATRA to inactive hydrox-
ylated forms and force an increase in ATRA intracellular concen-
tration.9 As shown in Figure 2G, talarozole could partly rescue the 
decrease in ATRA response observed in HRH1-KD cells, suggesting 
that effects on retinoid metabolism were, at least partially, involved 
in the lower response to ATRA.
As MAPK pathway activation is considered a key event in ATRA-
induced differentiation of HL-60,10 we also analysed its relationship 
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with HRH1-KD. Pharmacological Erk activation by UCN-01 was able 
to restore the HRH1-KD differentiation capacity, while the MEK in-
hibitor PD184352 abrogated their residual differentiation at higher 
doses of ATRA (Figure 2H). These effects had their correlates with 
the levels of Erk phosphorylation (Figure 2I,J).
In our study, we described an increase in HRH1 surface levels 
along healthy myeloid differentiation. Accordingly, the more differ-
entiated monocyte-like CMML cells showed high levels of HRH1, 
similarly to classical and intermediate monocytes. On the contrary, 
AML and MDS, neoplasms with highly misregulated myeloid dif-
ferentiation showed lower and heterogeneous HRH1 expression 
as compared with healthy myeloid cells. Rather than playing a lead 
role in myeloid malignancies, HRH1 may thus reflect the maturation 
state of abnormally differentiated cells. Then, the lower levels of 
HRH1 observed in AML and MDS could be related to the low levels 
of HRH1 seen in HSCs and non-myeloid blood cells, as previously 
reported (Figure 1A).2 On the other hand, pharmacological modu-
lation or CRISPR-mediated KD of HRH1 did not induce significant 
effects on chemosensitivity or basal differentiation state, while his-
tamine induced only a moderate reduction in clonogenic capacity, 
thus precluding the therapeutic potential of HRH1 targeting in my-
eloid malignancies and further supporting a minor role of HRH1, in 
line with previous results.5 Despite the lack of effects of HRH1 mod-
ulation in leukaemogenesis, our results establish a role for HRH1 in 
myeloid differentiation. Surprisingly and contrary to the otherwise 
inert effect of HRH1 depletion, HRH1-KD HL60 cells were refrac-
tory to differentiation, in sharp contrast with parental HL60. In ad-
dition, this was proven to be a general differentiation refractoriness, 
as the phenomenon was observed upon treatment with 3 different 
stimuli acting through separate signalling pathways. Mechanistically, 
we have hypothesized that the metabolism of ATRA could be in-
volved, as a decrease in CYP26 activity is able to partially overcome 
F I G U R E  1   HRH1 expression in healthy and malignant haematopoiesis. A, HRH1 expression was analysed by flow cytometry in healthy 
blood cell subsets (n = 3-10), CMML patient samples (n = 17), MDS patient samples (n = 45) and AML patient samples (n = 48). Each circle 
represents the mean value of each sample measured in triplicates. The right panel shows the expression of HRH1 in subsets of healthy-
donor monocytes (n = 3). Subsets were identified by marker phenotype (Classical, CD14+ CD16−; Intermediate, CD14+ CD16+, Non-classical, 
CD14dim CD16+). B, Clonogenicity assay for five AML primary samples and five AML cell lines treated with 500 µmol/L histamine (red 
bar), 10 µmol/L HTMT (orange bar, specific HRH1 agonist), 50 µmol/L fexofenadine (blue bar, specific HRH1 antagonist) or vehicle control 
(grey bar). Bars show mean ± SEM of the number of CFUS normalized to control. Each circle represents one sample (mean of a duplicate). 
Numbers of normalized CFUs are also represented in the lower heatmap-coloured table. *P < .05 in a paired parametric t test using non-
normalized values. C, A clonogenic assay for HPSCs was performed with lineage-depleted UCB cells (n = 4) treated with 500 µmol/L 
histamine (Hi, red), 10 µmol/L HTMT (HT, orange, specific HRH1 agonist), 50 µmol/L fexofenadine (Fe, blue, HRH1 antagonist), 50 µmol/L 
cetirizine (Ce, green, HRH1 antagonist) or vehicle control (C). Bars show mean ± SEM of the number of HPSC CFUs normalized to control. 
Each circle represents one sample (mean of a duplicate). D, Frequency of colony subtypes from (C). Error bars represent SEM. *P < .05 in a 
Two-way ANOVA with Geisser-Greenhouse correction
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the block in ATRA-induced differentiation. CYP26 has been previ-
ously involved in HSC self-renewal through bone marrow microen-
vironment.11 Also, HRH1-KD effects are probably acting upstream 
of MAPK signalling, because its pharmacological modulation is able 
to restore the lost differentiation capacity. Complementarily, HRH1 
was highly up-regulated upon ATRA treatment, strengthening the 
link between HRH1 and ATRA sensitivity. This link, then, works both 
ways: HRH1 is increased during differentiation, and at the same time 
is crucial for differentiation to take place.
Lately, chimeric antigen receptor (CAR) T cells have been proposed 
as promising strategies to eradicate AML. One of the main side effects 
associated with those therapies is the cytotoxicity resulting from an 
excessive immune activation known as cytokine release syndrome, 
managed, among others, with antihistamines.12-14 Even if our results 
demonstrate HRH1 expression in blasts from many AML patients, they 
also show that neither histamine nor antihistamines promote AML cell 
growth, discarding any relevance in the CAR-T cell context.
Taken together, the results obtained in this study suggest an in-
volvement of HRH1 in healthy and malignant myeloid differentia-
tion, that will need to be mechanistically elucidated in future studies.
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pharmacological modulation used in the experiments
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